EMAIL THIS PAGE TO A FRIEND

Cell chemical biology

Targeted Protein Degradation: from Chemical Biology to Drug Discovery.


PMID 28648379

Abstract

Traditional pharmaceutical drug discovery is almost exclusively focused on directly controlling protein activity to cure diseases. Modulators of protein activity, especially inhibitors, are developed and applied at high concentration to achieve maximal effects. Thereby, reduced bioavailability and off-target effects can hamper compound efficacy. Nucleic acid-based strategies that control protein function by affecting expression have emerged as an alternative. However, metabolic stability and broad bioavailability represent development hurdles that remain to be overcome for these approaches. More recently, utilizing the cell's own protein destruction machinery for selective degradation of essential drivers of human disorders has opened up a new and exciting area of drug discovery. Small-molecule-induced proteolysis of selected substrates offers the potential of reaching beyond the limitations of the current pharmaceutical paradigm to expand the druggable target space.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

905178
(S,R,S)-AHPC-C6-PEG1-C3-PEG1-butyl azide, ≥95%
C39H61N7O6S
905402
(S,R,S)-AHPC-C6-PEG1-C3-PEG1-butyl chloride, 95%
C39H61ClN4O6S
905232
(S,R,S)-AHPC-C6-PEG3-butyl amine hydrochloride, ≥95%
C38H61N5O7S · xHCl
905380
(S,R,S)-AHPC-C6-PEG3-butyl chloride, ≥95%
C38H59ClN4O7S
901503
(S,R,S)-AHPC-PEG1-Alkyne, ≥95%
C28H36N4O5S
901493
(S,R,S)-AHPC-PEG1-NH2 hydrochloride, ≥95%
C26H37N5O5S · xHCl
901517
(S,R,S)-AHPC-PEG2-Alkyne, ≥95%
C30H40N4O6S
910538
(S,R,S)-AHPC-PEG2-butyl alkyne, ≥95%
C34H48N4O6S
905216
(S,R,S)-AHPC-PEG2-butyl azide, ≥95%
C32H47N7O6S
901533
(S,R,S)-AHPC-PEG3-Alkyne, ≥95%
C32H44N4O7S
901851
(S,R,S)-AHPC-PEG4-Alkyne
C34H48N4O8S
909262
(S,R,S)-AHPC-PEG4-Azide, ≥95%
C32H47N7O8S
901848
(S,R,S)-AHPC-PEG4-NH2 hydrochloride, ≥95%
C32H49N5O8S · xHCl
901855
(S,R,S)-AHPC-PEG5-Alkyne
C36H52N4O9S
909351
(S,R,S)-AHPC-PEG5-azide, ≥98%
C34H51N7O9S
901850
(S,R,S)-AHPC-PEG5-NH2 hydrochloride
C34H54ClN5O9S
901873
(S,R,S)-AHPC-PEG6-Alkyne
C38H56N4O10S
909378
(S,R,S)-AHPC-PEG6-Azide, ≥95%
C36H55N7O10S
910597
(S,R,S)-AHPC-PEG6-butyl alkyne, ≥95%
C42H64N4O10S
905275
(S,R,S)-AHPC-PEG6-butyl amine hydrochloride, ≥95%
C40H65N5O10S · xHCl
901860
(S,R,S)-AHPC-PEG6-NH2 hydrochloride, ≥95%
C36H58ClN5O10S
901500
Pomalidomide-C3-CO2H, ≥95%
C17H17N3O6
901496
Pomalidomide-C6-CO2H, ≥98%
C20H23N3O6
906050
Pomalidomide-C6-PEG1-C3-PEG1-butyl iodide, ≥95%
C30H42IN3O7
910511
Pomalidomide-C6-PEG3-butyl alkyne, ≥95.0%
C31H41N3O8
901525
Pomalidomide-C9-CO2H, ≥95%
C23H29N3O6
901523
Pomalidomide-PEG1-Alkyne, ≥98%
C19H17N3O6
901527
Pomalidomide-PEG1-CO2H, ≥95%
C18H19N3O7
901516
Pomalidomide-PEG1-NH2 hydrochloride, ≥95%
C17H18N4O6 · xHCl
901529
Pomalidomide-PEG2-Alkyne, ≥95%
C21H21N3O7